HAMILTON, ON and BOSTON, Feb. 7, 2024
/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines, today
announced that the Company will present virtually at the
Oppenheimer 34th Annual Healthcare Life Sciences Conference on
Wednesday, February 14, 2024, at
10:00 a.m. ET. Presenting on behalf
of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A webcast of the event will be available on the "Events and
Presentations" page in the "Investors & Media" section of the
Company's website at https://ir.fusionpharma.com/events-webcasts. A
replay of the webcast will be archived on the Company's website for
90 days following the presentation date.
About Fusion
Fusion Pharmaceuticals is a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines. Fusion
connects alpha particle emitting isotopes to various targeting
molecules in order to selectively deliver the alpha emitting
payloads to tumors. Fusion's clinical portfolio includes: FPI-2265
targeting prostate specific membrane antigen (PSMA) for metastatic
castration resistant prostate cancer currently in a Phase 2 trial;
FPI-1434 targeting insulin-like growth factor 1 receptor currently
in a Phase 1 clinical trial; and FPI-2059, a small molecule
targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1
trial. In addition to a robust proprietary pipeline, Fusion has a
collaboration with AstraZeneca to jointly develop novel targeted
alpha therapies (TATs) and combination programs between Fusion's
TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and
immuno-oncology agents. The Company received IND clearance for
FPI-2068, the first novel TAT under the collaboration, which
targets EGFR-cMET. Fusion has also entered into a collaboration
with Merck to evaluate FPI-1434 in combination with Merck's
KEYTRUDA® (pembrolizumab) in patients with solid tumors
expressing IGF-1R. Fusion has a Good Manufacturing Practice (GMP)
compliant radiopharmaceutical manufacturing facility designed to
support manufacturing of the Company's growing pipeline of TATs. To
support Fusion's growing pipeline of TATs, the Company has signed
strategic actinium supply agreements with Niowave, Inc. and BWXT
Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations & Corporate
Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-302055615.html
SOURCE Fusion Pharmaceuticals